Is Artivion (AORT) overvalued or fairly valued?

MarketChacha shows Artivion's valuation in context — a trailing P/E of about 138.9, a forward P/E of about 34.7, a price-to-book of about 2.7 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Artivion's revenue?

Artivion reported revenue of $441.3M for FY2025, with net profit of $9.8M, per official filings.

What is the share price of Artivion (AORT)?

Artivion last traded at $25.01 (+0.3% on the day), as of 7/22/2026 — a delayed quote shown for education, not investment advice.

Artivion

AORT · NYSE · Healthcare · United States

$25.01+0.3%

Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 7:30 PM

Snapshot

TickerAORT

ExchangeNYSE

SectorHealthcare

IndustryMedical Devices

CountryUnited States

Employees1,800

HeadquartersKennesaw, United States

Market cap$1.2B

P/E (TTM)138.9

P/B2.7

Volume232.33K

Websiteartivion.com

Filings tracked4

About Artivion

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system. It also provides NEXUS DUO, an aortic arch system; NEXUS TRE, a custom-made three branch graft; E-vita thoracic 3G, a stent graft system; E-xtra Design Engineering, a range of stent graft systems for the treatment of aortic vascular diseases, such as TAAA and Artivex; E-nside, a multibranch stent graft system; E-tegra, an AAA stent graft system; E-ventus BX and Tuva BX balloon-expandable peripheral stent grafts; and E-liac, a stent graft used to treat aneurysmal iliac arteries. In addition, the company offers synthetic vascular grafts that are used in open aortic and peripheral vascular surgical procedures; BioGlue, a surgical sealant; CryoValve SG pulmonary heart valve; CryoPatch SG pulmonary cardiac patch; SynerGraft, a decellularization technology; vascular preservation services; and PhotoFix, a bovine pericardial patch fixated. It markets its products and preservation services primarily to physicians through a direct sales team to hospitals and other healthcare facilities. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

Profile as reported by Yahoo Finance.

Who owns it

Insiders4.5%
Institutions91.9%
Public & other3.6%

332 institutional holders

As reported by Yahoo Finance.

Top holders

Blackrock Inc.13.34%
FMR, LLC5.32%
Nomura Asset Management International Inc5.06%
Morgan Stanley4.67%
Vanguard Capital Management LLC4.02%
State Street Corporation3.47%
Perceptive Advisors Llc3.37%
Fred Alger Management, LLC2.49%

Largest institutional holders, as reported by Yahoo Finance (as of 3/31/2026).

Forensic scorecard

Latest ROE of 2.2% is on the low side — the business earns a modest return on shareholder capital.

Net margin trend-8.7% → 2.2%

Margin has expanded by about 10.9 points — the business is getting more profitable.

Return on equity2.2%

Latest ROE of 2.2% is on the low side — the business earns a modest return on shareholder capital.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $121.5M · EPS 0.10

Est. earnings growth -36.5%

Next fiscal year

Rev $539.8M · EPS 0.72

Est. earnings growth +63.0%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

$19.1652-wk range$48.25

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Market cap

$1.2B

Day change

+0.3%

P/E (TTM)

138.9

Fwd P/E

34.7

P/B

2.7

Beta

1.25

Revenue (FY2025)

$441.3M

Net margin

2.2%

ROE

2.2%

Revenue CAGR (2y)

+11.7%

EPS (FY2025)

0.21

Net profit (FY2025)

$9.8M

Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.

Ask MarketChacha about AORT

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$441.3M	$9.8M	0.21	2.2%	2.2%
FY2024	$388.5M	$-13.4M	-0.32	-3.4%	-4.8%
FY2023	$354.0M	$-30.7M	-0.75	-8.7%	-10.9%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q1	$116.3M	$1.4M	0.03	1.2%
2025Q3	$113.4M	$6.5M	0.13	5.7%
2025Q2	$113.0M	$1.3M	0.03	1.2%
2025Q1	$99.0M	$-505,000	-0.01	-0.5%
2024Q3	$95.8M	$-2.3M	-0.05	-2.4%
2024Q2	$98.0M	$-2.1M	-0.05	-2.2%
2024Q1	$97.4M	$7.5M	0.18	7.7%
2023Q3	$87.9M	$-9.8M	-0.24	-11.2%
2023Q2	$89.3M	$-3.4M	-0.08	-3.8%
2023Q1	$83.2M	$-13.5M	-0.33	-16.3%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Reg FD disclosure, Other events, Exhibits
SEC5/18/2026material
8-K — Shareholder vote results
SEC5/15/2026material
10-Q filing
SEC5/8/2026
8-K — Material agreement, Results of operations, Exhibits
SEC5/7/2026material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.